Skip to content
ACC.26 Día 1 (Parte 1) episode artwork

Mar 29, 2026 45 min

ACC.26 Día 1 (Parte 1)

from CARDIOSÍNTESIS PODCAST

En este episodio de Cardiosíntesis, exploramos los ensayos clínicos más importantes de este primer día en el ACC 2026 de Nueva Orleans. - Effects Of Tirzepatide Compared With Dulaglutide On Expanded Cardiorenal Outcomes - Reliability Of CAC=0 To Exclude Coronary Plaque In Diverse Global Cohorts - Outcomes In Patients With Atrial Fibrillation Randomized To Receive Left Atrial Appendage Closure Or Oral Anticoagulation: Primary Results Of The CHAMPION-AF Clinical Trial - Primary Left Ventricular Unloading In Anterior ST-Segment Elevation Myocardial Infarction (STEMI) Without Cardio genic Shock - Kardinal: A Phase 2 Study Of Tonlamarsen For The Treatment Of Uncontrolled Hypertension - Evolocumab In Patients Without Significant Atherosclerosis: Results From VESALIUS-CV

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

ACC.26 Día 1 (Parte 1)

0:00 45:52

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of CARDIOSÍNTESIS PODCAST?

This episode is 45 minutes long.

When was this CARDIOSÍNTESIS PODCAST episode published?

This episode was published on March 29, 2026.

Can I download this CARDIOSÍNTESIS PODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.